TNF and Cowden disease: This difference was consistently observed in the individual UC and CD disease groups and was more pronounced in patients with CD [37.2% of patients with CD treated with 5-ASA during vedolizumab maintenance had a history of prior anti-TNFα treatment vs 72.2% of patients treated without 5-ASA].